-
effectivehealthcare-admin.ahrq.gov/products/methods-guidance-tests-genetic/methods
December 01, 2019 - with a particular genetic change who exhibit signs and symptoms of a disorder.” 3 Penetrance is a key factor … This is a good example of incorporating a key preanalytic factor (family history), that has an important
-
effectivehealthcare-admin.ahrq.gov/products/glaucoma/abstract
December 01, 2019 - legal blindness in the country. 3,4 For primary open-angle glaucoma (POAG), race is an important risk factor
-
effectivehealthcare-admin.ahrq.gov/products/stroke-afib-update/research-2018
May 01, 2020 - include new antithrombotic strategies, devices, and oral anticoagulants (oral direct thrombin inhibitors, factor
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/diagnostic-error-executive-summary.pdf
August 01, 2023 - The causal and risk factor literature was strongest
for patient and illness characteristics and relatively
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/disparities-quality-improvement_executive.pdf
August 01, 2012 - One study of cardiovascular risk factor modification
showed no meaningful reduction in health disparities … Cardiovascular Disease
Studies of CAD risk factor control included men with
CAD risk factors at clinical … The interventions for CAD risk factor control included
intensive patient education and self-management … For studies of cardiovascular risk factor control, outcomes
consisted of intermediate clinical variables … Responses of black and white males to
the special intervention program of the Multiple Risk Factor
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/misuse-prescription-protocol-amendment.pdf
November 26, 2024 - Quality
In Prognosis Studies (QUIPS) tool13 which covers study participation, attrition,
prognostic factor … Judging the quality of evidence in reviews of
prognostic factor research: adapting the GRADE framework
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/autoimmune-disease-rapid-research.pdf
November 01, 2024 - There
is weak evidence for lowering of other inflammatory markers like Tumor necrosis factor
alpha … weak evidence for other outcomes like anti-citrullinated protein
autoantibodies (ACPAs), rheumatoid factor … • Other outcomes: We find weak evidence for other outcomes like ACPAs, rheumatoid
factor, life impact … area and severity index; RA: rheumatoid arthritis; RCT: randomized controlled trial; RF: rheumatoid factor … periodontal treatment; RA: rheumatoid arthritis;
RCT: randomized controlled trial; RF: rheumatoid factor
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/rheumatoid-arthritis-medicine-update_research-protocol.pdf
May 15, 2017 - Rates of RA development are increased in monozygotic
twins, implicating genetics as a contributing factor … disease activity remains moderate or high, double or triple combination
DMARDs or a tumor necrosis factor … Food and Drug
Administration; RA = rheumatoid arthritis; TNF = tumor necrosis factor; ts = targeted … disease-modifying antirheumatic drug; KQ = Key Question; RA =
rheumatoid arthritis; TNF = tumor necrosis factor … rheumatoid arthritis; RCT = randomized controlled trial; SR = systematic review; TNF = tumor
necrosis factor
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/methods-guidance-tests-genetic_methods.pdf
July 01, 2012 - with a particular genetic change who exhibit signs and symptoms of a
disorder.”3 Penetrance is a key factor … This is a good example of
incorporating a key preanalytic factor (family history), that has an important
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/s66.pdf
October 01, 2007 - These drugs include tumor necrosis factor antagonists (anti-
TNF) and an interleukin-1 antagonist (anti-IL … Anti-Tumor Ne-
crosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy
Study Group. … Adalimumab, a fully
human anti-tumor necrosis factor alpha monoclonal antibody, for the
treatment of … Eligibility of patients in routine care for major
clinical trials of anti-tumor necrosis factor alpha … Tumor necrosis factor inhibitors for rheumatoid
arthritis. N Engl J Med. 2006;355:704–712.
42.
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/cancer-pancreas_research-protocol.pdf
August 09, 2013 - or tumor
characteristic
Another test: Effect of
patient factor or tumor
characteristic
Staging … FNA
• Sedation-related effects of EUS-FNA
(e.g., nausea, vomiting)
3a P1 or P2 or
P3
Patient factor … Comparator patient
factor
See the list of harms for KQ 3
3b P1 or P2 or
P3
Same list as KQ 1a … Source: www.effectivehealthcare.ahrq.gov
Published online: August 9, 2013
9
An important factor … Although this factor will not be addressed formally in the review as a KQ, we plan
to collect and provide
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/TND_0129_07-13-2009.pdf
January 01, 2009 - Effective Health Care
Topic Number: 0168
Document Completion Date: 6-9-10
1
Results of Topic Selection Process & Next Steps
Cesarean birth in low-risk women will go forward for refinement as a systematic review. The scope of
this topic, including populations, interventions, comparato…
-
effectivehealthcare-admin.ahrq.gov/health-topics/tanning
Use sunscreen with sun protective factor (SPF) 15 or higher.
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/worker-safety-wellness-protocol.pdf
October 26, 2024 - Impact of Healthcare Worker Safety and Wellness: A Systematic Review
Evidence-based Practice Center Systematic Review Protocol
Project Title: Impact of Healthcare Worker Safety and Wellness:
A Systematic Review
I. Background and Objectives for the Systematic Review
As trained professionals who pr…
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/mrsa-screening_research.pdf
June 01, 2013 - Prioritized list of risk factor research questions with PICOTS information .............. … Prioritized list of risk factor research questions with PICOTS information ................... 19
Table … Prioritized list of risk factor research questions with PICOTS information
Research
Question Population … Prioritized list of risk factor research questions with PICOTS information
Research Question Population
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/assessing-applicability.ppt
January 01, 2009 - Assessing Applicability
Assessing Applicability
Prepared for:
The Agency for Healthcare Research and Quality (AHRQ)
Training Modules for Systematic Reviews Methods Guide
www.ahrq.gov
Assessing Applicability
Systematic Review Process Overview
*
Systematic Review Process Overview
This slide illustrates the steps…
-
effectivehealthcare-admin.ahrq.gov/products/methods-guidance-applicability/methods
May 01, 2020 - populations. 31 Reviewers should routinely capture information on baseline or control group risk as a factor
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/breast-biopsy-update_executive.pdf
September 01, 2014 - method, these groups were treated together as
‘multiple methods’ in statistical analyses for that factor … complementary
sources: (1) within-study evidence (i.e., comparisons of
test performance over levels of a factor … Twenty studies provided information that allowed an
evaluation of the impact of any factor on test performance … within-study analyses and meta-regression
analyses were insufficient to confirm (or exclude) any
single factor … needle biopsy did
not allow investigation of the impact of factors on adverse
events and no individual factor
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/kidney-disease-medicine_research-protocol.pdf
November 01, 2010 - subgroups of people; (3) Whether the feasibility, efficacy, and/or harms of treatment for
the risk factor … filtration rate, and hematocrit with 25-year
incidence of end-stage renal disease in the multiple risk factor
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/methods-future-value-of-information_research.pdf
June 01, 2011 - Another factor that
should be considered is the likelihood that relevant information may be imperfectly … In other cases, a factor is considered, but without much
rigorous analysis. … VOI in Millions ICER-Trial £11 ICER-Trial ICER-Trial ICER-Trial $46 $308,000 £1 $64
Applied scale factor … for population at
risk* - 5.01 - - - 1.00 1.00 5.01 5.01
Applied scale factor for time horizon … for
population at risk* 1.0 - - - 13975§ 1 19 19 -
Applied scale factor for time
horizon 1 - - -